Modulation of FcγRIIa/IIb protein expression on monocytes before treatment and 2 weeks after initiation of HD-DXM therapy. (A) Representative Western blotting of monocyte lysates immunoprecipitated with anti–FcγRII cocktail and blotted with goat anti–human FcγRIIa, FcγRIIb, and β-actin are shown. (B) Changes of FcγRIIa and FcγRIIb protein expression on monocytes in patients after HD-DXM treatment. Fourteen of the 23 patients had increased FcγRIIb expression. *Patients who still showed no FcγRIIb expression after HD-DXM therapy.